Difference between revisions of "Sahebjam S, et al. Br. J. Cancer (2013) cited as Ref 589 in DOI: 10.1038/s41392-020-0110-5 (Q9852)"
Jump to navigation
Jump to search
(Created claim: Volume (P103): 109, #quickstatements; #temporary_batch_1590009084631) |
(Created claim: Page(s) (P105): 943-949, #quickstatements; #temporary_batch_1590074839150) |
||
| (One intermediate revision by the same user not shown) | |||
| Property / title | |||
| + | A phase I study of the combination of ro4929097 and cediranib in patients with advanced solid tumours (PJC-004/NCI 8503) (English) | ||
| Property / title: A phase I study of the combination of ro4929097 and cediranib in patients with advanced solid tumours (PJC-004/NCI 8503) (English) / rank | |||
| + | Normal rank | ||
| Property / Page(s) | |||
| + | 943-949 | ||
| Property / Page(s): 943-949 / rank | |||
| + | Normal rank | ||
Latest revision as of 15:46, 21 May 2020
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
| Language | Label | Description | Also known as |
|---|---|---|---|
| English |
Sahebjam S, et al. Br. J. Cancer (2013) cited as Ref 589 in DOI: 10.1038/s41392-020-0110-5
|
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
|
Statements
Sahebjam S
0 references
2013
0 references
Br. J. Cancer
0 references
109
0 references
A phase I study of the combination of ro4929097 and cediranib in patients with advanced solid tumours (PJC-004/NCI 8503) (English)
0 references
943-949
0 references
